A Clinical Pharmacological Perspective on Intraperitoneal Chemotherapy

Area of Science:

• Oncology
• Pharmacology
• Cancer Therapeutics

Background:

• Peritoneal metastases (PM) pose a significant challenge in various cancers due to poor prognosis and limited systemic chemotherapy effectiveness.
• The peritoneal-plasma barrier restricts drug penetration, hindering effective treatment of PM.
• Intraperitoneal (IP) chemotherapy provides a locoregional approach to achieve higher drug concentrations in the peritoneal cavity, enhancing efficacy and reducing systemic toxicity.

Purpose of the Study:

• To provide a comprehensive review of the pharmacological rationale behind IP chemotherapy for treating PM.
• To discuss drug characteristics, administration variables, and pharmacokinetic (PK) data relevant to IP therapy.
• To evaluate recent advancements and future potential of IP chemotherapy, including nanoparticle formulations.

Main Methods:

• Review of existing literature on IP chemotherapy administration methods (HIPEC, PIPAC, CBIP).
• Analysis of pharmacokinetic principles governing drug distribution and retention within the peritoneal cavity.
• Evaluation of PK data for commonly used chemotherapeutic agents and novel formulations in IP therapy.

Main Results:

• IP chemotherapy methods offer distinct pharmacokinetic advantages for PM treatment.
• Drug properties and administration parameters significantly influence IP drug exposure and retention.
• Emerging nanoparticle formulations show potential for improved drug delivery and targeted action.

Conclusions:

• The pharmacokinetic rationale strongly supports IP chemotherapy for PM.
• Ongoing clinical trials are crucial for validating efficacy.
• Innovations in drug formulations and administration protocols are key to optimizing IP chemotherapy outcomes and minimizing toxicity.